Triple Digit Gains…That’s What’s For Breakfast!


Vitality Biopharma (VBIO) was a company we started looking at around $0.98 and ever since then, things have really picked up. If you’ve been in chat, you’ve seen this explode, first hand and today it just keeps getting better.

There was a ceiling at $1.47 for the last few days but after the company announced that it had received approval from both the DEA and the State of California Research Advisory Panel, VBIO has been crushing records! Last week we saw it set a new 52-week high at $2.69 and when everyone expected a slow week to close out the year, VBIO has done it again, hitting highs of $3.30 and marking an incredible run in December

VBIO has managed to push toward new highs week in and week out…so this could be just the beginning of a real breakout run. Since we first began focusing on this alert, VBIO has seen a total run of 237% on some seriously bullish volume. As this continues to trend higher, we’ll obviously be keeping a very close watch on it heading into 2017. If this is the first time you’re hearing about it, check out VBIO, pull up a multi week chart, and get your butt in chat!


Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares We own zero shares of (VBIO), which we purchased in the open market. We plan to sell the “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please Read Our Full Disclaimer Here


About Author

Leave A Reply